#USA #Cambridge #Nona Biosciences #Lonza #CNS Diseases

Nona Biosciences and Lonza Collaborate on Innovative CNS Technology

In a breakthrough announcement on July 1, 2026, Nona Biosciences, a global leader in biotechnology, revealed a strategic collaboration with Lonza to develop pioneering blood-brain barrier (BBB)-crossing technology. This advancement targets central nervous system (CNS) diseases and represents a significant leap in biotherapeutic innovation.

The Collaboration Explained

Nona's proprietary Harbour Mice® platform, which excels in producing fully human heavy-chain antibodies (HCAbs), will be at the forefront of this joint effort. The goal is to create next-generation single-domain antibodies designed specifically for efficient crossing of the blood-brain barrier. This combination aims to facilitate the delivery of a range of therapeutic agents into the CNS, potentially transforming the landscape of treatment for various CNS disorders.

Both parties stand to gain substantially from this partnership. Nona will not only receive upfront payments and options from Lonza but also a share in future revenue generated from licensing agreements created as part of this collaboration. Dr. Jingsong Wang, Chairman of Nona Biosciences, expressed his enthusiasm by stating, “This partnership validates Nona's platform and strategic direction in next-gen delivery technologies.” He highlighted how Lonza’s global reach and regulatory know-how would accelerate the advancement of the BBB-crossing technology.

The Technology's Impact

The technology the partnership aims to develop could unlock numerous possibilities in CNS drug development. Current challenges in delivering therapeutics across the blood-brain barrier have limited treatment options for patients with neurological disorders. By harnessing the capabilities of Nona's Harbour Mice® platform along with Lonza’s established GS Gene Expression System® and GlycoConnect® bioconjugation technology, the collaboration looks to optimize selected candidates for BBB-crossing. Dr. Di Hong, CEO of Nona, emphasized this by stating that the collaboration will generate differentiated, fully human single-domain binders capable of overcoming challenging barriers in drug delivery.

The progress achieved through this collaboration is expected not just to foster technological innovations but also to result in substantial licensing and commercialization opportunities. As emphasized by Peter Droc, Lonza's Head of Licensing, the acquisition of IP rights to Nona's BBB technology allows for immediate translation into viable therapeutics, reducing development complexity and accelerating access for patients.

Future Perspectives

Looking ahead, the collaboration aims to reshape CNS treatment paradigms. As Nona and Lonza continue their work, they aspire not just to create new drugs but to set a new standard for addressing the pressing challenges of CNS disorders. With the combination of Nona’s innovative antibody platforms and Lonza’s manufacturing prowess, the future looks promising for patients and healthcare practitioners alike. The innovation spearheaded by this partnership underscores the ongoing evolution in biotechnology, paving the way for enhanced therapeutic approaches and improved patient outcomes.

About Nona Biosciences

Nona Biosciences is a wholly owned subsidiary of HBM Holding Limited, committed to advancing biotherapeutic innovation through cutting-edge technologies and integrated solutions. Their proprietary Harbour Mice® platform generates fully human monoclonal antibodies and offers exceptional versatility for diverse applications, including bispecific antibodies and more. This strategic collaboration with Lonza marks a significant step in their mission to revolutionize drug delivery and treatment options, demonstrating their dedication to improving patient health globally. For further information, visit www.nonabio.com.